

HISTOPLASMOSIS IN ANIMALS

Introduction

Histoplasmosis was the most common endemic mycosis in dogs in the United States and Canada between 1964 and 1976 (1). The case rates per 100,000 patient-years-at-risk at 14 colleges of veterinary medicine for histoplasmosis was 2.5 times higher than blastomycosis and 3.5 times higher than coccidioidomycosis (1). The relative risk in dogs today is unknown. In humans in the United States, histoplasmosis was the most common cause for hospitalization, 1.5 times more common than coccidioidomycosis and 4.4 times more common than blastomycosis (2). Many veterinarians are unaware that histoplasmosis is the most common endemic mycosis.

Histoplasmosis usually causes pulmonary and/or disseminated disease. While histoplasmosis is not transmissible from animal to human, concurrent infection is not uncommon because of shared exposure. Familiarity with the clinical manifestations may alert a veterinarian to consider the diagnosis. Antigen detection in urine and serum may provide a rapid diagnosis, precluding the need for invasive procedures to obtain specimens for organism identification in many patients. Antibody testing may be useful in cases with negative results by antigen testing. Itraconazole is the treatment of choice, and therapy may be monitored by antigen testing. Itraconazole absorption and metabolism vary considerably, at times causing undetectable or toxic blood levels, and blood level measurement is encouraged to assure adequate drug exposure.

Epidemiology

Histoplasmosis caused by *Histoplasma capsulatum* variety *capsulatum* is endemic in certain parts of North and South America. In some endemic areas, histoplasmosis was the most common systemic mycosis in animals. Between 1964 and 1976, 14 schools of veterinary medicine in the United States and Canada participated in a study of systemic mycoses and noted rates per hundred thousand patient years of 62 for histoplasmosis, 25 for blastomycosis and 17 for coccidioidomycosis (1).

In a study of necropsy findings in dogs from Kentucky, 36.1% had positive cultures for *H. capsulatum* compared to 0.7% for *Blastomyces dermatitidis* (3). In a similar study from Loudoun County, Virginia *H. capsulatum* was isolated from 44% of apparently healthy dogs and cats (4). In Kentucky, 47% of dogs (5) and 50% of Thoroughbred horses exhibited *Histoplasma* skin test reactivity, while only 7.3% of horses demonstrated *Blastomyces* skin test reactivity (6). Histoplasmosis was twice as frequent in animals from rural areas as from urban areas (3). Histoplasmosis also occurs outside of the traditional endemic area (7;8).

Several dog breeds have been shown to have an increased risk of histoplasmosis, including the Pointer, Weimeraner and Brittany spaniel (2). Mean age at diagnosis from one large study was 3.6 years (2). Cats appear to have a similar incidence of histoplasmosis as that seen in dogs. Persian cats are slightly over-represented, while Siamese cats are marginally under-represented (55). Interestingly, indoor-only cats remain at risk for

MVista® *Histoplasma* Antigen Quantitative EIA

Test Code: 310

Specimen Type: Urine, Serum, BAL, CSF & other
pipetteable fluid

***Histoplasma* Antibody Immunodiffusion**

Test Code: 321

Specimen Type: Serum

histoplasmosis (49, 88). Cases also occur in horses (9-20), llamas (21), sea mammals (22-24) and wild animals (8;25-36)

Pathogenesis

Histoplasmosis is caused by inhalation of microconidia or hyphal fragments. Although intestinal lesions are prominent in dogs with disseminated histoplasmosis, experimental infection by gastric inoculation failed to induce disease in dogs (37). All mammals are susceptible to histoplasmosis, but cases have been reported most often in dogs, cats, and horses. Birds, because of their higher body temperature, are not susceptible to natural infection (38) but may be infected experimentally, causing infection localized to their feathers (39). Histoplasmosis is not transmissible from patient to patient, or from animals to man, but disease in an animal may be a harbinger of infection in humans who were exposed at the same time (40).

Cellular immunity is critical in defense against *H. capsulatum*, based on analysis of risk factors for severe disease. The microconidia are inhaled and in the lungs they attract dendritic cells, neutrophils and macrophages, which phagocytose the organism, which transform into yeasts and multiply unchecked in the non-immune subject. During the first two weeks, the infection progresses and disseminates hematogenously throughout the reticuloendothelial system. By day 14 of infection, specific T cell immunity develops, halting proliferation of the yeast and progression of the infection. Evidence for self-limited dissemination includes demonstration of calcified granulomas in the spleen and liver in healthy individuals in endemic areas for histoplasmosis, which contain non-viable organisms and occasional isolation of *H. capsulatum* from extrapulmonary specimens in patients with acute pulmonary histoplasmosis.

Cytokines that are most important in immunity to *H. capsulatum* include IL-12, IL-18, TNF- α and interferon- γ . A successful T cell response requires dendritic cells, CD4 and CD8 T lymphocytes and activated macrophages. T cells produce interferon- γ and tumor necrosis factor- α , which activate macrophages to kill *Histoplasma* yeast. If these elements are impaired, the yeast. The importance of TNF- α in humans is highlighted by the emerging recognition of histoplasmosis as a major opportunistic infection in patients treated with TNF inhibitors.

While histoplasmosis is self-limited in over 95% of healthy humans, chronic and/or progressive disease may occur more often in animals. Thirty one to 44% of euthanized dogs and cats in endemic areas had evidence for histoplasmosis (41-43). Chronic infection also is common in bats (44;45). Interestingly the tissue reaction in bats was minimal or absent, possibly explaining their inability to eradicate the organism (44-47). The infection rate varied markedly in different genera of bats, suggesting genetic differences in susceptibility (48). *Histoplasma* was not isolated from wild-caught mice, suggesting that their immune response was able to kill the organism (38).

Clinical Presentation

The severity of clinical manifestations correlates with the intensity of exposure and the underlying health of the exposed individual. Cole described rapidly progressive fatal course over two to four weeks in 10% of dogs with histoplasmosis, and chronic progressive course over two to 20 months in 90% (49). Demonstration of positive cultures of pulmonary and extrapulmonary tissues of apparently healthy dogs and cats from endemic areas

suggest that the clinical findings may be overlooked in many cases. Syndromes most commonly identified include pneumonia, mediastinal lymphadenitis, and progressive disseminated histoplasmosis.

Pulmonary. Pneumonia is the most common manifestation in humans, and probably in animals. Dogs usually present with signs of fever, dyspnea, cough and lethargy. Radiographic findings characteristically include diffuse nodules, referred to as "cotton tuft" lesions (50) (Figure 3) or diffuse interstitial infiltrates, often accompanied by hilar lymphadenopathy (51). Alveolar infiltrates are rarely seen (51).

Mediastinal Lymphadenitis. Enlarged hilar or mediastinal lymph nodes may impinge upon the airways and cause cough and respiratory distress (52;53). Radiographs show tracheobronchial lymphadenopathy usually accompanied by interstitial pneumonia. The outcome has ranged from spontaneous resolution to progressive obstruction of the airways and death. Concurrent dissemination may occur (53).

Progressive Disseminated Histoplasmosis. Fever, weight loss, reduced activity, anemia, and interstitial lung disease are the most common manifestations in cats (54), while diarrhea, intestinal blood loss, anemia and reduced activity predominate in dogs (49;55) (Table 1), but any tissue may be involved.

Bone lesions are common in cats (54). Central nervous system and ocular lesions may be found in all animal species. Endocarditis also has been reported, noted in seven of 17 (41%) necropsy cases in dogs (57). Other tissues commonly involved at necropsy include liver, spleen, abdominal lymph nodes, and less frequently adrenal glands, kidneys, and pancreas (49).

Pulmonary involvement occurs in most cases and is usually manifested as labored breathing (54;55). Radiographs typically show diffuse interstitial, miliary or nodular infiltrates (54).

Abnormal physical findings include hepatomegaly, splenomegaly, eye lesions or discharge, subcutaneous nodules, and skin lesions (54;55). The common laboratory abnormalities are anemia, leukopenia, thrombocytopenia, hypoalbuminemia, increased liver enzyme activity, creatinine elevation, and hypercalcemia (58). The untreated course ranges from subclinical chronic infection to a rapidly fatal illness.

Equine Abortion. Infections in the fetus or neonatal foal may occur, causing the mare to abort or the foal to die soon after birth (18;20;59). Pulmonary and disseminated involvement usually are present in the fetus or newborn (20). In most cases the mare appears healthy but the placenta is involved.

Table 1. Clinical findings in dogs (55) and cats (54;56)		
Finding	Dogs (%)	Cats (%)
Fever	25	58
Weight Loss	42	83
Respiratory Symptoms	50	39-42
Chest Radiograph Abnormal	NS*	87-88
Lethargy/Depression	58	66
Intestinal-Diarrhea, Bleeding	83	NS
Hepatomegaly	NS	33
Splenomegaly	NS	17
Lymphadenopathy	33	33
Eye Lesions or Discharge	NS	24-42
Bone Lesions	NS	18
Skin Lesions	NS	8
Anemia	58	100
Hepatic Enzyme ↑	50	40
*NS = not stated		

Diagnosis

Prompt diagnosis offers the greatest chance for recovery from histoplasmosis, made possible by early therapy (60). Today most cases are diagnosed by detection of Histoplasma antigen in the urine and/or serum or demonstration of yeast in the body fluids or tissues. Antibody detection may be useful in cases in which antigen tests and/or pathology are negative or specimens are not available for pathology.

Pathology. As most reports required demonstration of Histoplasma yeasts in tissues or body fluids or positive culture for diagnosis (54;55), the sensitivity of pathology is uncertain. In humans the detection of antigen in the urine or serum is more sensitive than pathology or culture (61). Other limitations of pathology are the requirements to perform invasive procedures to obtain specimens for evaluation and that the pathologists are experienced with recognition of fungal organisms.

Antigen Detection. A galactomannan antigen in the cell wall of proliferating Histoplasma yeasts is released into the tissues and blood, and excreted in the urine. Antigen was detected in the urine of 94% of cats (82) and dogs [Cunningham in press] with histoplasmosis. The highest sensitivity is achieved by testing both urine and serum. Antigen also may be detected in the respiratory secretions in patients with pulmonary histoplasmosis and cerebrospinal fluid of those with meningitis. Antigen levels decline during treatment and increase with relapse (62), providing a tool for monitoring therapy.

The antigen found in histoplasmosis cross reacts with that found in blastomycosis (63). Furthermore, the clinical findings and endemic distribution overlap. Thus, differentiation of the two mycoses may be difficult, but treatment is the same, reducing the need to distinguish histoplasmosis and blastomycosis. Antibody testing may distinguish these two mycoses (64).

Culture. Culture is rarely performed, but usually is positive in disseminated cases (42). The major limitation is the slow growth rate and risk to laboratory personnel from exposure to the mycelial form of the fungus.

Antibody Detection. Antibody detection has not been adequately evaluated in animals with histoplasmosis. The sensitivity of complement fixation (CF) was reported to be about 90% (65). Others reported a sensitivity of CF to be only 11% (57). The CF test is often uninterpretable in dogs because their serum is anti-complementary, and CF is not offered commercially at veterinary reference laboratories. Agar gel immunodiffusion (AGID) is offered commercially, but the sensitivity was only 25% in one report (3). Positive results have been reported in cats (50) and horses with histoplasmosis (20). Sensitivity may be improved using an enzyme immunoassay, which has been described in blastomycosis (63) and under development for histoplasmosis (66).

Molecular Techniques. PCR has been reported to be positive in the tissues of several animal species with histoplasmosis, mostly in dogs (67-71) but also in other species (22;23;29;67;68;72). Most reports, however, describe results in single cases. No studies have reported the sensitivity and specificity and none have reported results on body fluids, or compared PCR to other diagnostic methods. Additional studies are needed to assess the role of PCR for diagnosis of histoplasmosis.

Treatment

Guidelines for treatment are provided, but textbooks and other reviews should be used for more thorough instruction on antifungal treatment in animals. Most information is based on experience in cats treated with fluconazole or itraconazole (73) but amphotericin B is preferred for more severe cases. Relapse has occurred after stopping therapy in 40% of successfully treated cases (73).

Itraconazole. The usual dosage is 5 (74) to 10 mg/kg (75;76) given once or twice daily. At least 4-6 months of therapy is typically administered. A study in cats found itraconazole to be effective in six of 13 cases, while 3 were euthanized or died, four required a change in therapy to fluconazole because of lack of response or toxicity (73). Four of the 13 cats experienced a relapse. Treatment should be continued until at least 1-2 months after resolution of clinical signs and probably until antigen is no longer detected in urine, based on experience in blastomycosis (62). Antigen concentration should be monitored at 3 and 6 months after discontinuation of therapy, and upon recurrence of clinical findings suggestive for relapse. In another report of five cases treated with itraconazole for 3 to 8 months, all responded to therapy and remained well with follow-up from 24 to 70 months (77). Amphotericin B was given for two treatments in 2 of the 5 cases (77).

Brand-name itraconazole (Sporanox®, Janssen Pharmaceuticals) or generic itraconazole should be used, as compounded powder formulations have poor bioavailability (78) (23). Blood levels should be measured 14 (dogs) to 21 (cats) days after beginning therapy, and the preferred range is 3.0 to 10.0 µg/mL as measured by bioassay, and at least 1.0 µg/mL by HPLC. Blood levels above 10.0 µg/mL may cause more toxicity and are unnecessary for response to therapy: dosage may be reduced in patients with blood levels above 10.0 µg/mL. Inability to achieve concentrations above 3 µg/ml or toxicity are reasons to change to fluconazole. Itraconazole is eliminated by hepatic metabolism through cytochrome P450 3A4, and blood levels may be affected by medications that interact with that enzyme

Itraconazole may cause a variety of adverse effects, most commonly loss of appetite, anorexia, vomiting, or diarrhea, which may be related to high blood levels (79). Bilirubin and hepatic enzymes also may be elevated, in association with clinical evidence for hepatitis in some cases; and should be monitored during therapy. Serum alanine aminotransferase (ALT) greater than 200 U/L may warrant discontinuation of itraconazole (80). Itraconazole may be restarted at half of the former dose. Ulcerative dermatitis was also observed in 7.5% of dogs receiving itraconazole at 10 mg/kg/d (81).

Fluconazole. Response to fluconazole was similar to that with itraconazole in cats (73). Of 17 cats treated with fluconazole, 3 died or were euthanized, 9 completed therapy, one switched to itraconazole because of poor response, and 4 relapsed. Some veterinarians prefer fluconazole for treatment of cases involving the CNS, eye, or prostate because, as a consequence of its smaller molecular size and lipophilicity, it achieves better penetration into these tissues. Other reasons for choosing fluconazole include lower cost and better tolerability. Doses of at least 10 mg/kg/day are recommended.

Other azoles. Ketoconazole is infrequently used because, based on studies in blastomycosis (82), it is less effective and causes more adverse effects than itraconazole. One of five cats with histoplasmosis responded to ketoconazole (50). Posaconazole and voriconazole are more active than fluconazole and have been used successfully in humans with histoplasmosis, but have not been evaluated in animals. Histoplasma also is susceptible to isavuconazole, a newly approved antifungal azole, but clinical studies for treatment of histoplasmosis have not been reported. The newer azoles are more expensive than itraconazole or fluconazole.

Amphotericin B. Amphotericin B is the treatment of choice in severe cases in humans and induces a clinical response more rapidly than itraconazole (83) or fluconazole. Reasons for amphotericin B's superiority include its fungicidal mode of action and intravenous route of administration, rapidly providing therapeutic blood concentrations. Administration of amphotericin B for the first 3 to 7 days of therapy may improve early survival, after which treatment could be changed to itraconazole or fluconazole. Lipid forms of amphotericin B are better tolerated but more expensive than the deoxycholate formulation. Renal function and serum electrolytes should be monitored during treatment.

Adjunctive therapy. Schulman noted rapid clinical improvement in ten dogs with mediastinal lymphadenitis causing airway obstruction, five of which also received antifungal treatment (52). Corticosteroids also may be helpful in cases of diffuse pulmonary histoplasmosis complicated by respiratory insufficiency. Concurrent antifungal therapy is recommended to reduce the risk for progressive dissemination caused by corticosteroid-induced immunosuppression.

Monitoring Therapy. The antigen test often is used in deciding when to stop therapy and to diagnose relapse. In 27 dogs with blastomycosis, antigen levels in urine were negative in 70% at the time of treatment discontinuation (62). (<http://onlinelibrary.wiley.com/doi/10.1111/jvim.12306/abstract>) Relapse occurred in 7 dogs (26%), 2 of which had a positive urine antigen at treatment discontinuation, and was associated with a rise in antigenuria in 5. The authors recommended continuing therapy until the clinical findings, including eye exam, resolved, chest radiographs were normal or stable and urinary antigen was negative. A reasonable approach would be to test for antigenuria every 3 months during therapy, at 3 and 6 months after stopping therapy, and if relapse is suspected.

Table 2. Treatment recommendations
Itraconazole 5-10 mg/kg/day or fluconazole 10 mg/mg/day for 4-6 months ¹ Consider amphotericin B ² in severe cases, including respiratory insufficiency ³ Monitor antigen every 3 months and if suspect relapse Itraconazole blood level ⁴
¹ some cases may require more than 6 months of treatment; ² lipid formulation better tolerated ³ may benefit from adjunctive corticosteroid therapy; ⁴ day 14 (dogs) to 21 (cats) of therapy to ensure levels between 1.0 and 10 µg/mL and if suspect relapse or itraconazole toxicity.

Reference List

- (1) Selby LA, Becker SV, Hayes HW, Jr. Epidemiologic risk factors associated with canine systemic mycoses. *Am J Epidemiol* **1981 Feb**;113(2):133-9.
- (2) Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE. Hospitalizations for endemic mycoses: a population-based national study. *Clin Infect Dis* **2006 Mar 15**;42(6):822-5.
- (3) Turner C, Smith CD, Furcolow ML. Frequency of isolation of *Histoplasma capsulatum* and *Blastomyces dermatitidis* from dogs in Kentucky. *Am J Vet Res* **1972 Jan**;33(1):137-41.
- (4) Rowley DA. Pathological studies of histoplasmosis; preliminary report on fifty cats and fifty dogs from Loudoun County, Virginia. *Public Health Monogr* **1956**;39:268-71.
- (5) Marx MB, Eastin CE, Turner C, Smith CD, Roeckel I, Furcolow ML. The influence of amphotericin B upon *Histoplasma* infection in dogs. *Arch Environ Health* **1970 Nov**;21(5):649-55.
- (6) Marx MB, Jones MB, Kimberlin DS, Furcolow ML. Survey of histoplasmin and blastomycin test reactors among thoroughbred horses in central Kentucky. *Am J Vet Res* **1972 Aug**;33(8):1701-5.
- (7) Johnson LR, Fry MM, Anez KL, Proctor BM, Jang SS. Histoplasmosis infection in two cats from California. *J Am Anim Hosp Assoc* **2004 Mar**;40(2):165-9.
- (8) Clothier KA, Villanueva M, Torain A, Reinl S, Barr B. Disseminated histoplasmosis in two juvenile raccoons (*Procyon lotor*) from a nonendemic region of the United States. *J Vet Diagn Invest* **2014 Mar**;26(2):297-301.
- (9) Katayama Y, Kuwano A, Yoshihara T. Histoplasmosis in the lung of a race horse with yersiniosis. *J Vet Med Sci* **2001 Nov**;63(11):1229-31.
- (10) Panciera RJ. Histoplasma (*Histoplasma capsulatum*) infection in a horse. *Cornell Vet* **1969 Apr**;59(2):306-12.
- (11) Soliman R, Saad MA, Refai M. Studies on histoplasmosis *farciminosii* (epizootic lymphangitis) in Egypt. III. Application of a skin test ('Histofarcin') in the diagnosis of epizootic lymphangitis in horses. *Mykosen* **1985 Sep**;28(9):457-61.
- (12) Abou-Gabal M, Hassan FK, Al-Siad AA, Al-Karim KA. Study on equine histoplasmosis "epizootic lymphangitis". *Mykosen* **1983 Mar**;26(3):145-51.
- (13) al-Ani FK. Epizootic lymphangitis in horses: a review of the literature. *Rev Sci Tech* **1999 Dec**;18(3):691-9.
- (14) Blackford J. Superficial and deep mycoses in horses. *Vet Clin North Am Large Anim Pract* **1984 Mar**;6(1):47-58.
- (15) Conti-Diaz IA, Alvarez BJ, Gezuele E, Gonzalez MH, Duarte J, Falcon J. [Intradermal reaction survey with paracoccidioidin and histoplasmin in horses]. *Rev Inst Med Trop Sao Paulo* **1972 Nov**;14(6):372-6.

- (16) Cooper VL, Kennedy GA, Kruckenberg SM, Vorhies MW. Histoplasmosis in a miniature Sicilian burro. J Vet Diagn Invest **1994 Oct**;6(4):499-501.
- (17) Goetz TE, Coffman JR. Ulcerative colitis and protein losing enteropathy associated with intestinal salmonellosis and histoplasmosis in a horse. Equine Vet J **1984 Sep**;16(5):439-41.
- (18) Hall AD. An equine abortion due to histoplasmosis. Vet Med Small Anim Clin **1979 Feb**;74(2):200-1.
- (19) Jones MB, Gonzalez-Ochoa A, Marx MB, Furcolow ML. Survey of histoplasmin skin test reactions among horses in Mexico. Am J Vet Res **1972 Aug**;33(8):1707-9.
- (20) Rezabek GB, Donahue JM, Giles RC, et al. Histoplasmosis in horses. J Comp Pathol **1993 Jul**;109(1):47-55.
- (21) Woolums AR, DeNicola DB, Rhyan JC, et al. Pulmonary histoplasmosis in a llama. J Vet Diagn Invest **1995 Oct**;7(4):567-9.
- (22) Burek-Huntington KA, Gill V, Bradway DS. Locally acquired disseminated histoplasmosis in a northern sea otter (*Enhydra lutris kenyoni*) in Alaska, USA. J Wildl Dis **2014 Apr**;50(2):389-92.
- (23) Jensen ED, Lipscomb T, Van Bonn B, Miller G, Fradkin JM, Ridgway SH. Disseminated histoplasmosis in an Atlantic bottlenose dolphin (*Tursiops truncatus*). J Zoo Wildl Med **1998 Dec**;29(4):456-60.
- (24) Wilson TM, Kierstead M, Long JR. Histoplasmosis in a harp seal. J Am Vet Med Assoc **1974 Nov** 1;165(9):815-7.
- (25) Frame SR, Mehdi NA, Turek JJ. Naturally occurring mucocutaneous histoplasmosis in a rabbit. J Comp Pathol **1989 Oct**;101(3):351-4.
- (26) Jensen HE, Bloch B, Henriksen P, Dietz HH, Schonheyder H, Kaufman L. Disseminated histoplasmosis in a badger (*Meles meles*) in Denmark. APMIS **1992 Jul**;100(7):586-92.
- (27) Bauder B, Kubber-Heiss A, Steineck T, Kuttin ES, Kaufman L. Granulomatous skin lesions due to histoplasmosis in a badger (*Meles meles*) in Austria. Med Mycol **2000 Jun**;38(3):249-53.
- (28) Eisenberg T, Seeger H, Kasuga T, Eskens U, Sauerwald C, Kaim U. Detection and characterization of *Histoplasma capsulatum* in a German badger (*Meles meles*) by ITS sequencing and multilocus sequencing analysis. Med Mycol **2013 May**;51(4):337-44.
- (29) Highland MA, Chaturvedi S, Perez M, Steinberg H, Wallace R. Histologic and molecular identification of disseminated *Histoplasma capsulatum* in a captive brown bear (*Ursus arctos*). J Vet Diagn Invest **2011 Jul**;23(4):764-9.
- (30) Raju NR, Langham RF, Bennett RR. Disseminated histoplasmosis in a Fennec fox. J Am Vet Med Assoc **1986 Nov** 1;189(9):1195-6.
- (31) Weller RE, Dagle GE, Malaga CA, Baer JF. Hypercalcemia and disseminated histoplasmosis in an owl monkey. J Med Primatol **1990**;19(7):675-80.

- (32) Baskin GB. Disseminated histoplasmosis in a SIV-infected rhesus monkey. *J Med Primatol* **1991 Jul**;20(5):251-3.
- (33) Woolf A, Gremillion-Smith C, Sundberg JP, Chandler FW. Histoplasmosis in a striped skunk (*Mephitis mephitis* Schreber) from southern Illinois. *J Wildl Dis* **1985 Oct**;21(4):441-3.
- (34) Butler TM, Hubbard GB. An epizootic of histoplasmosis *duboisii* (African histoplasmosis) in an American baboon colony. *Lab Anim Sci* **1991 Oct**;41(5):407-10.
- (35) Butler TM, Gleiser CA, Bernal JC, Ajello L. Case of disseminated African histoplasmosis in a baboon. *J Med Primatol* **1988**;17(3):153-61.
- (36) Brandao J, Woods S, Fowlkes N, et al. Disseminated histoplasmosis (*Histoplasma capsulatum*) in a pet rabbit: case report and review of the literature. *J Vet Diagn Invest* **2014 Jan**;26(1):158-62.
- (37) Farrell RL, Cole CR, Prior JA, Saslaw S. Experimental histoplasmosis, I. Methods for production of histoplasmosis in dogs. *Proc Soc Exp Biol Med* **1953 Oct**;84(1):51-4.
- (38) Emmons CW, Rowley DA, Olson BJ, et al. Histoplasmosis; proved occurrence of inapparent infection in dogs, cats and other animals. *Am J Hyg* **1955 Jan**;61(1):40-4.
- (39) Tewari RP, Campbell CC. Isolation of *Histoplasma capsulatum* from feathers of chickens inoculated intravenously and subcutaneously with the yeast phase of the organism. *Sabouraudia* **1965 Feb**;4(1):17-22.
- (40) Davies SF, Colbert RL. Concurrent human and canine histoplasmosis from cutting decayed wood. *Ann Intern Med* **1990 Aug** 1;113(3):252-3.
- (41) Rowley DA, HABERMAN RT, Emmons CW. Histoplasmosis: pathologic studies of fifty cats and fifty dogs from Loudoun County, Virginia. *J Infect Dis* **1954 Jul**;95(1):98-108.
- (42) FATTAL AR, Schwarz J, Straub M. Isolation of *Histoplasma capsulatum* from lymph nodes of spontaneously infected dogs. *Am J Clin Pathol* **1961 Aug**;36:119-24.
- (43) Turner C, Smith CD, Furcolow ML. The efficiency of serologic and cultural methods in the detection of infection with *Histoplasma* and *Blastomyces* in mongrel dogs. *Sabouraudia* **1972 Mar**;10(1):1-5.
- (44) Greer DL, McMurray DN. Pathogenesis of experimental histoplasmosis in the bat, *Artibeus lituratus*. *Am J Trop Med Hyg* **1981 May**;30(3):653-9.
- (45) Tesh RB, Schneidau JD, Jr. Experimental infection of North American insectivorous bats (*Tadarida brasiliensis*) with *Histoplasma capsulatum*. *Am J Trop Med Hyg* **1966 Jul**;15(4):544-50.
- (46) Taylor ML, Chavez-Tapia CB, Vargas-Yanez R, et al. Environmental conditions favoring bat infection with *Histoplasma capsulatum* in Mexican shelters. *Am J Trop Med Hyg* **1999 Dec**;61(6):914-9.

- (47) Hasenclever HF, Shacklette MH, Hunter AW, George E, Schwarz J. The use of cultural and histologic methods for the detection of *Histoplasma capsulatum* in bats: absence of a cellular response. *Am J Epidemiol* **1969 Jul**;90(1):77-83.
- (48) Klite PD, Diercks FH. HISTOPLASMA CAPSULATUM IN FECAL CONTENTS AND ORGANS OF BATS IN THE CANAL ZONE. *Am J Trop Med Hyg* **1965 May**;14:433-9.
- (49) Cole CR, Farrell RL, CHAMBERLAIN DM, Prior JA, Saslaw S. Histoplasmosis in animals. *J Am Vet Med Assoc* **1953 Jun**;122(915):471-3.
- (50) Kabli S, Koschmann JR, Robertstad GW, Lawrence J, Ajello L, Redetzke K. Endemic canine and feline histoplasmosis in El Paso, Texas. *J Med Vet Mycol* **1986**;24:41-50.
- (51) Ettinger S, Feldman EC. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat. 5th ed. **1999**.
- (52) Schulman RL, McKiernan BC, Schaeffer DJ. Use of corticosteroids for treating dogs with airway obstruction secondary to hilar lymphadenopathy caused by chronic histoplasmosis: 16 cases (1979-1997). *J Am Vet Med Assoc* **1999 May 1**;214(9):1345-8.
- (53) Ackerman N, Cornelius LM, Halliwell WH. Respiratory distress associated with histoplasma-induced tracheobronchial lymphadenopathy in dogs. *J Am Vet Med Assoc* **1973 Oct 15**;163(8):963-7.
- (54) Clinkenbeard KD, Cowell RL, Tyler RD. Disseminated histoplasmosis in cats: 12 cases (1981-1986). *J Am Vet Med Assoc* **1987 Jun 1**;190(11):1445-8.
- (55) Clinkenbeard KD, Cowell RL, Tyler RD. Disseminated histoplasmosis in dogs: 12 cases (1981-1986). *J Am Vet Med Assoc* **1988 Dec 1**;193(11):1443-7.
- (56) Davies C, Troy GC. Deep mycotic infections in cats. *J Am Anim Hosp Assoc* **1996 Sep**;32(5):380-91.
- (57) Mitchell M, Stark DR. Disseminated canine histoplasmosis: a clinical survey of 24 cases in Texas. *Can Vet J* **1980 Mar**;21(3):95-100.
- (58) Hodges RD, Legendre AM, Adams LG, et al. Itraconazole for the treatment of histoplasmosis in cats. *J Vet Intern Med* **1994 Nov**;8(6):409-13.
- (59) Saunders JR, Matthiesen RJ, Kaplan W. Abortion due to histoplasmosis in a mare. *J Am Vet Med Assoc* **1983 Nov 15**;183(10):1097-9.
- (60) Balows A, Ausherman RJ, Hopper JM. Practical diagnosis and therapy of canine histoplasmosis and blastomycosis. *J Am Vet Med Assoc* **1966 Mar 15**;148(6):678-84.
- (61) Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. *Clin Infect Dis* **2011 Sep**;53(5):448-54.

- (62) Foy DS, Trepanier LA, Kirsch EJ, Wheat LJ. Serum and urine blastomyces antigen concentrations as markers of clinical remission in dogs treated for systemic blastomycosis. *J Vet Intern Med* **2014 Mar**;28(2):305-10.
- (63) Spector D, Legendre AM, Wheat J, et al. Antigen and antibody testing for the diagnosis of blastomycosis in dogs. *J Vet Intern Med* **2008 Jul**;22(4):839-43.
- (64) Richer SM, Smedema ML, Durkin MM, et al. Development of a Highly Sensitive and Specific Blastomycosis Antibody Enzyme Immunoassay Using Blastomyces dermatitidis Surface Protein BAD-1. *Clin Vaccine Immunol* **2014 Feb**;21(2):143-6.
- (65) Smith CD, Furcolow ML, Hulker P. Effect of immunosuppressants on dogs exposed two and one-half years previously to Blastomyces dermatitidis. *Am J Epidemiol* **1976 Sep**;104(3):299-305.
- (66) Richer SM, Smedema ML, Wheat L.J. Improvement of the Sensitivity and Specificity of Histoplasmosis Antibody Detection. 2014 May 17; **2014**.
- (67) Pratt CL, Sellon RK, Spencer ES, Johnson TW, Righter DJ. Systemic mycosis in three dogs from nonendemic regions. *J Am Anim Hosp Assoc* **2012 Nov**;48(6):411-6.
- (68) Reginato A, Giannuzzi P, Ricciardi M, et al. Extradural spinal cord lesion in a dog: first case study of canine neurological histoplasmosis in Italy. *Vet Microbiol* **2014 Jun 4**;170(3-4):451-5.
- (69) Sano A, Ueda Y, Inomata T, et al. [Two cases of canine histoplasmosis in Japan]. *Nippon Ishinkin Gakkai Zasshi* **2001**;42(4):229-35.
- (70) Schumacher LL, Love BC, Ferrell M, Desilva U, Fernando R, Ritchey JW. Canine intestinal histoplasmosis containing hyphal forms. *J Vet Diagn Invest* **2013 Mar**;25(2):304-7.
- (71) Ueda Y, Sano A, Tamura M, et al. Diagnosis of histoplasmosis by detection of the internal transcribed spacer region of fungal rRNA gene from a paraffin-embedded skin sample from a dog in Japan. *Vet Microbiol* **2003 Jul 17**;94(3):219-24.
- (72) Reyes-Montes MR, Rodriguez-Arellanes G, Perez-Torres A, et al. Identification of the source of histoplasmosis infection in two captive maras (Dolichotis patagonum) from the same colony by using molecular and immunologic assays. *Rev Argent Microbiol* **2009 Apr**;41(2):102-4.
- (73) Reinhart JM, Kukanich KS, Jackson T, Harkin KR. Feline histoplasmosis: Fluconazole therapy and identification of potential sources of Histoplasma species exposure. *J Feline Med Surg* **2012 Jun 26**.
- (74) Kerl ME. Update on canine and feline fungal diseases. *Vet Clin North Am Small Anim Pract* **2003 Jul**;33(4):721-47.
- (75) Bromel C, Sykes JE. Epidemiology, diagnosis, and treatment of blastomycosis in dogs and cats. *Clin Tech Small Anim Pract* **2005 Nov**;20(4):233-9.
- (76) Krohne SG. Canine systemic fungal infections. *Vet Clin North Am Small Anim Pract* **2000 Sep**;30(5):1063-90.

- (77) Aulakh HK, Aulakh KS, Troy GC. Feline histoplasmosis: a retrospective study of 22 cases (1986-2009). J Am Anim Hosp Assoc **2012 May**;48(3):182-7.
- (78) Mazepa AS, Trepanier LA, Foy DS. Retrospective comparison of the efficacy of fluconazole or itraconazole for the treatment of systemic blastomycosis in dogs. J Vet Intern Med **2011 May**;25(3):440-5.
- (79) Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis **2009 Sep 15**;49(6):928-30.
- (80) Legendre AM. Blastomycosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. Fourth ed. St. Louis: Elsevier, **2012**. p. 606-14.
- (81) Legendre AM, Rohrbach BW, Toal RL, Rinaldi MG, Grace LL, Jones JB. Treatment of blastomycosis with itraconazole in 112 dogs. J Vet Intern Med **1996 Nov**;10(6):365-71.
- (82) Legendre AM, Selcer BA, Edwards DF, Stevens R. Treatment of canine blastomycosis with amphotericin B and ketoconazole. J Am Vet Med Assoc **1984 May 15**;184(10):1249-54.
- (83) Hage CA, Kirsch EJ, Stump TE, et al. Histoplasma Antigen Clearance during Treatment of Histoplasmosis in Patients with AIDS Determined by a Quantitative Antigen Enzyme Immunoassay. Clin Vaccine Immunol **2011 Apr**;18(4):661-6.